C:\stnweb\Queries\4.str





chain nodes :
7 8 16 17 18 19 20 30 31 32 33
ring nodes :
1 2 3 4 5 10 11 12 13 14 15 21 22 23 24 25 26
chain bonds :
2-7 4-8 5-17 10-16 11-31 12-30 13-17 14-32 15-33 16-18 18-19 19-20
ring bonds :
1-2 1-5 2-3 3-4 4-5 10-11 10-15 11-12 12-13 13-14 14-15 21-22 21-26 22-23
23-24 24-25 25-26
exact/norm bonds :
2-3 2-7 3-4 4-8 10-16 11-31 12-30 14-32 15-33
exact bonds :
1-2 1-5 4-5 5-17 13-17 16-18 18-19 19-20
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15 21-22 21-26 22-23 23-24 24-25 25-26
isolated ring systems :
containing 1 : 10 : 21 :

G1:O,S

G2:F,CH3,OH,NH2,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 30:CLASS 31:CLASS 32:CLASS
33:CLASS

```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  JAN 27  Source of Registration (SR) information in REGISTRY updated
                  and searchable
 NEWS  4  JAN 27  A new search aid, the Company Name Thesaurus, available in
                  CA/CAplus
 NEWS  5  FEB 05  German (DE) application and patent publication number format
                  changes
 NEWS  6  MAR 03  MEDLINE and LMEDLINE reloaded
 NEWS  7  MAR 03  MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 03  FRANCEPAT now available on STN
 NEWS  9  MAR 29  Pharmaceutical Substances (PS) now available on STN
 NEWS 10  MAR 29  WPIFV now available on STN
 NEWS 11  MAR 29  No connect hour charges in WPIFV until May 1, 2004
 NEWS 12  MAR 29  New monthly current-awareness alert (SDI) frequency in RAPRA

 NEWS EXPRESS  MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:12:32 ON 26 APR 2004

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:12:37 ON 26 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 APR 2004  HIGHEST RN 676578-75-9
DICTIONARY FILE UPDATES:  23 APR 2004  HIGHEST RN 676578-75-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.
```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

0 27 S 28
Page 1-A



Page 1-B



Page 2-A



Page 2-B



Page 3-A



Page 3-B



Page 4-A



Page 4-B

```
VAR G1=27/28
REP G19=(0-2) 17-14 17-18
REP G20=(1-2) 15-5 15-11
VPA 19-23/24 S
NODE ATTRIBUTES:
NSPEC   IS R      AT   1
NSPEC   IS R      AT   2
NSPEC   IS R      AT   3
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS C      AT   6
```

```
NSPEC   IS C      AT   7
NSPEC   IS R      AT   8
NSPEC   IS R      AT   9
NSPEC   IS R      AT  10
NSPEC   IS R      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS C      AT  14
NSPEC   IS C      AT  15
NSPEC   IS C      AT  16
NSPEC   IS C      AT  17
NSPEC   IS C      AT  18
NSPEC   IS C      AT  19
NSPEC   IS C      AT  20
NSPEC   IS R      AT  21
NSPEC   IS R      AT  22
NSPEC   IS R      AT  23
NSPEC   IS R      AT  24
NSPEC   IS R      AT  25
NSPEC   IS R      AT  26
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  14 15 17 18 19 27 28
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  28

STEREO ATTRIBUTES: NONE


=> s l1
SAMPLE SEARCH INITIATED 12:16:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      6 TO ITERATE

100.0% PROCESSED       6 ITERATIONS                                5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            6 TO      266
PROJECTED ANSWERS:               5 TO      234

L2            5 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 12:16:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    184 TO ITERATE

100.0% PROCESSED     184 ITERATIONS                             115 ANSWERS
SEARCH TIME: 00.00.01

L3          115 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               157.94     158.15
```

FILE 'HCAPLUS' ENTERED AT 12:16:42 ON 26 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Apr 2004 VOL 140 ISS 18
FILE LAST UPDATED: 25 Apr 2004 (20040425/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> **s l3**
L4 892 L3

=> **file reg**
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.36	160.51

FILE 'REGISTRY' ENTERED AT 12:17:12 ON 26 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 APR 2004 HIGHEST RN 676578-75-9
DICTIONARY FILE UPDATES: 23 APR 2004 HIGHEST RN 676578-75-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L5 STRUCTURE UPLOADED

=> **l5**
L5 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d l5
L5 HAS NO ANSWERS
L5 STR

F 36 C 53 O 58 N M2

O 33 S 34
Page 1-A



Page 1-B



Page 2-A

modulator. A method of treating symptoms related to type II diabetes wherein said symptoms are selected from the group consisting of hyperglycemia, hyperinsulinemia, inadequate, glucose clearance, obesity, hypertension and high glucocorticoid levels in a mammal comprising administering a therapeutically effective amt. of a compd. of title compds. A method of treating diseases assocd. with an excess or deficiency of glucocorticoids, said diseases selected from the group consisting of diabetes, obesity, Syndrome X, Cushing's Syndrome, Addison's disease, inflammatory diseases such as asthma, rhinitis and arthritis, allergy, autoimmune disease, immunodeficiency, anorexia, cachexia, bone loss or bone frailty, and wound healing comprising administering a therapeutically effective amt. of a compd. of title compds.

IT **122320-73-4**, Rosiglitazone
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(prepn. of substituted aminobenzene derivs. as glucocorticoid receptor modulators)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 2001:904164 HCAPLUS
DOCUMENT NUMBER: 136:20065
TITLE: 5-[4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl]thiazolidine-2,4-dione hydriodide as pharmaceutical
INVENTOR(S): Craig, Andrew Simon; Ho, Tim Chien Ting; Millan, Michael John



Page 2-B



Page 3-A



Page 3-B



Page 4-A



Page 4-B

```
VAR G1=33/34
VAR G2=35/36/37/38
REP G19=(0-2) 17-14 17-18
REP G20=(1-2) 15-5 15-11
VPA 19-23/24 S
NODE ATTRIBUTES:
HCOUNT   IS M3      AT  36
HCOUNT   IS M1      AT  37
HCOUNT   IS M2      AT  38
NSPEC    IS R       AT   1
NSPEC    IS R       AT   2
NSPEC    IS R       AT   3
```

```
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS C      AT   6
NSPEC   IS C      AT   7
NSPEC   IS R      AT   8
NSPEC   IS R      AT   9
NSPEC   IS R      AT  10
NSPEC   IS R      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS C      AT  14
NSPEC   IS C      AT  15
NSPEC   IS C      AT  16
NSPEC   IS C      AT  17
NSPEC   IS C      AT  18
NSPEC   IS C      AT  19
NSPEC   IS C      AT  20
NSPEC   IS R      AT  21
NSPEC   IS R      AT  22
NSPEC   IS R      AT  23
NSPEC   IS R      AT  24
NSPEC   IS R      AT  25
NSPEC   IS R      AT  26
NSPEC   IS C      AT  27
NSPEC   IS C      AT  28
NSPEC   IS C      AT  29
NSPEC   IS C      AT  30
NSPEC   IS C      AT  31
NSPEC   IS C      AT  32
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  14 15 17 18 19 33 34 35 36 37 38
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  38

STEREO ATTRIBUTES: NONE


=> s 15
SAMPLE SEARCH INITIATED 12:20:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      6 TO ITERATE

100.0% PROCESSED       6 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            6 TO      266
PROJECTED ANSWERS:               0 TO        0

L6            0 SEA SSS SAM L5

=> s 15 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 12:20:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    184 TO ITERATE
```

```
100.0% PROCESSED     184 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.02

L7             0 SEA SSS FUL L5

=>
L8       STRUCTURE UPLOADED

=> d 18
L8 HAS NO ANSWERS
L8                 STR
 F 36 C 53 O 58 N M2 H 39

 O 33 S 34
Page 1-A
```



Page 1-B



Page 2-A



Page 2-B



Page 3-A



Page 3-B



Page 4-A



Page 4-B

```
VAR G1=33/34
VAR G2=35/36/37/38/39
REP G19=(0-2) 17-14 17-18
REP G20=(1-2) 15-5 15-11
VPA 19-23/24 S
NODE ATTRIBUTES:
HCOUNT   IS M3      AT  36
HCOUNT   IS M1      AT  37
HCOUNT   IS M2      AT  38
NSPEC    IS R       AT   1
NSPEC    IS R       AT   2
NSPEC    IS R       AT   3
```

```
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS C      AT   6
NSPEC   IS C      AT   7
NSPEC   IS R      AT   8
NSPEC   IS R      AT   9
NSPEC   IS R      AT  10
NSPEC   IS R      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS C      AT  14
NSPEC   IS C      AT  15
NSPEC   IS C      AT  16
NSPEC   IS C      AT  17
NSPEC   IS C      AT  18
NSPEC   IS C      AT  19
NSPEC   IS C      AT  20
NSPEC   IS R      AT  21
NSPEC   IS R      AT  22
NSPEC   IS R      AT  23
NSPEC   IS R      AT  24
NSPEC   IS R      AT  25
NSPEC   IS R      AT  26
NSPEC   IS C      AT  27
NSPEC   IS C      AT  28
NSPEC   IS C      AT  29
NSPEC   IS C      AT  30
NSPEC   IS C      AT  31
NSPEC   IS C      AT  32
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  14 15 17 18 19 33 34 35 36 37 38 39
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  39

STEREO ATTRIBUTES: NONE


=> s 18
SAMPLE SEARCH INITIATED 12:21:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      6 TO ITERATE

100.0% PROCESSED       6 ITERATIONS                              4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            6 TO      266
PROJECTED ANSWERS:               4 TO      200

L9            4 SEA SSS SAM L8

=> s 18 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 12:21:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    184 TO ITERATE
```

```
100.0% PROCESSED     184 ITERATIONS                          103 ANSWERS
SEARCH TIME: 00.00.01

L10          103 SEA SSS FUL L8

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   312.94     473.45

FILE 'HCAPLUS' ENTERED AT 12:21:24 ON 26 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 26 Apr 2004  VOL 140 ISS 18
FILE LAST UPDATED: 25 Apr 2004  (20040425/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> s l10
L11          892 L10

=>
L12      STRUCTURE UPLOADED

=> d l12
L12 HAS NO ANSWERS
L12              STR
```

F 34 C 35 O 36 N M2 H 37

O 31 S 32



Page 1-A



Page 1-B



Page 2-A



Page 2-B



Page 3-A





Page 3-B



Page 4-A



Page 4-B

```
VAR G1=31/32
VAR G2=33/34/35/36/37
REP G19=(0-2) 17-16 17-18
REP G20=(1-2) 15-5 15-11
VPA 18-21/22 S
NODE ATTRIBUTES:
HCOUNT  IS M2     AT  15
HCOUNT  IS M2     AT  16
HCOUNT  IS M2     AT  17
HCOUNT  IS M3     AT  34
HCOUNT  IS M1     AT  35
HCOUNT  IS M2     AT  36
NSPEC   IS R      AT   1
NSPEC   IS R      AT   2
NSPEC   IS R      AT   3
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS C      AT   6
NSPEC   IS C      AT   7
NSPEC   IS R      AT   8
NSPEC   IS R      AT   9
NSPEC   IS R      AT  10
NSPEC   IS R      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS C      AT  14
NSPEC   IS C      AT  15
NSPEC   IS C      AT  16
NSPEC   IS C      AT  17
NSPEC   IS C      AT  18
NSPEC   IS R      AT  19
NSPEC   IS R      AT  20
NSPEC   IS R      AT  21
NSPEC   IS R      AT  22
NSPEC   IS R      AT  23
NSPEC   IS R      AT  24
NSPEC   IS C      AT  25
NSPEC   IS C      AT  26
NSPEC   IS C      AT  27
NSPEC   IS C      AT  28
NSPEC   IS C      AT  29
NSPEC   IS C      AT  30
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  14 15 16 17 18 31 32 33 34 35 36 37
DEFAULT ECLEVEL IS LIMITED
```

```
GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  37

STEREO ATTRIBUTES: NONE


=> s l12
 REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.




SAMPLE SEARCH INITIATED 12:23:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      6 TO ITERATE

100.0% PROCESSED       6 ITERATIONS                              4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            6 TO      266
PROJECTED ANSWERS:               4 TO      200

L13           4 SEA SSS SAM L12



L14          4 L13

=>
L15     STRUCTURE UPLOADED

=> d l15
L15 HAS NO ANSWERS
L15             STR
```

F 34 C 35 O 36 N M2 H 37

O 31 S 32

Page 1-A



Page 1-B



Page 2-A



Page 2-B



Page 3-A





Page 3-B



Page 4-A



Page 4-B

```
VAR G1=31/32
VAR G2=33/34/35/36/37
REP G19=(0-2) 17-16 17-18
REP G20=(1-2) 15-5 15-11
VPA 18-21/22 S
NODE ATTRIBUTES:
HCOUNT  IS M2     AT  15
HCOUNT  IS M2     AT  16
HCOUNT  IS M2     AT  17
HCOUNT  IS M3     AT  34
HCOUNT  IS M1     AT  35
HCOUNT  IS M2     AT  36
NSPEC   IS R      AT   1
NSPEC   IS R      AT   2
NSPEC   IS R      AT   3
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS C      AT   6
NSPEC   IS C      AT   7
NSPEC   IS R      AT   8
NSPEC   IS R      AT   9
NSPEC   IS R      AT  10
NSPEC   IS R      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS C      AT  14
NSPEC   IS C      AT  15
NSPEC   IS C      AT  16
NSPEC   IS C      AT  17
NSPEC   IS C      AT  18
NSPEC   IS R      AT  19
NSPEC   IS R      AT  20
NSPEC   IS R      AT  21
NSPEC   IS R      AT  22
NSPEC   IS R      AT  23
NSPEC   IS R      AT  24
NSPEC   IS C      AT  25
NSPEC   IS C      AT  26
NSPEC   IS C      AT  27
NSPEC   IS C      AT  28
NSPEC   IS C      AT  29
NSPEC   IS C      AT  30
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  14 15 16 17 18 31 32 33 34 35 36 37
DEFAULT ECLEVEL IS LIMITED
```

```
GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  37

STEREO ATTRIBUTES: NONE


=> s l15
 REGlstRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.




SAMPLE SEARCH INITIATED 12:24:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      6 TO ITERATE

100.0% PROCESSED       6 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            6 TO      266
PROJECTED ANSWERS:               4 TO      200

L16            4 SEA SSS SAM L15



L17          4 L16

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     7.08     493.17

FILE 'REGISTRY' ENTERED AT 12:25:51 ON 26 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 APR 2004  HIGHEST RN 676578-75-9
DICTIONARY FILE UPDATES:  23 APR 2004  HIGHEST RN 676578-75-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html
```

```
=>
L18      STRUCTURE UPLOADED

=> d l18
L18 HAS NO ANSWERS
L18                STR
 F 34 C 35 O 36 N M2 H 37

 O 31 S 32
```

Page 1-A



Page 1-B



Page 2-A



Page 2-B



Page 3-A





Page 3-B



Page 4-A



Page 4-B

```
VAR G1=31/32
VAR G2=33/34/35/36/37
REP G19=(0-2) 17-16 17-18
REP G20=(1-2) 15-5 15-11
VPA 18-21/22 S
NODE ATTRIBUTES:
HCOUNT  IS M2     AT  15
HCOUNT  IS M2     AT  16
HCOUNT  IS M2     AT  17
HCOUNT  IS M3     AT  34
HCOUNT  IS M1     AT  35
HCOUNT  IS M2     AT  36
NSPEC   IS R      AT   1
NSPEC   IS R      AT   2
NSPEC   IS R      AT   3
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS C      AT   6
NSPEC   IS C      AT   7
NSPEC   IS R      AT   8
NSPEC   IS R      AT   9
NSPEC   IS R      AT  10
NSPEC   IS R      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS C      AT  14
NSPEC   IS C      AT  15
NSPEC   IS C      AT  16
NSPEC   IS C      AT  17
NSPEC   IS C      AT  18
NSPEC   IS R      AT  19
NSPEC   IS R      AT  20
NSPEC   IS R      AT  21
NSPEC   IS R      AT  22
NSPEC   IS R      AT  23
NSPEC   IS R      AT  24
NSPEC   IS C      AT  25
NSPEC   IS C      AT  26
NSPEC   IS C      AT  27
NSPEC   IS C      AT  28
NSPEC   IS C      AT  29
NSPEC   IS C      AT  30
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  14 15 16 17 18 31 32 33 34 35 36 37
DEFAULT ECLEVEL IS LIMITED
```

```
GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  37

STEREO ATTRIBUTES: NONE


=> s l18
SAMPLE SEARCH INITIATED 12:26:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      6 TO ITERATE

100.0% PROCESSED       6 ITERATIONS                                 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            6 TO      266
PROJECTED ANSWERS:               4 TO      200

L19           4 SEA SSS SAM L18

=> s l18 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 12:26:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    178 TO ITERATE

100.0% PROCESSED     178 ITERATIONS                               101 ANSWERS
SEARCH TIME: 00.00.01

L20         101 SEA SSS FUL L18

=> file hcaplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                155.42     648.59

FILE 'HCAPLUS' ENTERED AT 12:26:18 ON 26 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 26 Apr 2004  VOL 140 ISS 18
FILE LAST UPDATED: 25 Apr 2004  (20040425/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.
```

```
=> s l20
L21         891 L20

=> d his

     (FILE 'HOME' ENTERED AT 12:12:32 ON 26 APR 2004)

     FILE 'REGISTRY' ENTERED AT 12:12:37 ON 26 APR 2004
L1                STRUCTURE UPLOADED
L2              5 S L1
L3            115 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 12:16:42 ON 26 APR 2004
L4            892 S L3

     FILE 'REGISTRY' ENTERED AT 12:17:12 ON 26 APR 2004
L5                STRUCTURE UPLOADED
L6              0 S L5
L7              0 S L5 FULL
L8                STRUCTURE UPLOADED
L9              4 S L8
L10           103 S L8 FULL

     FILE 'HCAPLUS' ENTERED AT 12:21:24 ON 26 APR 2004
L11           892 S L10
L12               STRUCTURE UPLOADED
                  S L12

     FILE 'REGISTRY' ENTERED AT 12:23:45 ON 26 APR 2004
L13             4 S L12

     FILE 'HCAPLUS' ENTERED AT 12:23:46 ON 26 APR 2004
L14             4 S L13
L15               STRUCTURE UPLOADED
                  S L15

     FILE 'REGISTRY' ENTERED AT 12:24:18 ON 26 APR 2004
L16             4 S L15

     FILE 'HCAPLUS' ENTERED AT 12:24:19 ON 26 APR 2004
L17             4 S L16

     FILE 'REGISTRY' ENTERED AT 12:25:51 ON 26 APR 2004
L18               STRUCTURE UPLOADED
L19             4 S L18
L20           101 S L18 FULL

     FILE 'HCAPLUS' ENTERED AT 12:26:18 ON 26 APR 2004
L21           891 S L20

=> s l4 and blackler, p?/au
              11 BLACKLER, P?/AU
L22            7 L4 AND BLACKLER, P?/AU

=> d l22, 1-7, ibib abs fhitstr, 1-7

L22  ANSWER 1 OF 7  HCAPLUS  COPYRIGHT 2004 ACS on STN
```

Full Text | Citing References

```
ACCESSION NUMBER:         2000:772629  HCAPLUS
```

DOCUMENT NUMBER: 133:340315
TITLE: Therapeutic action and properties of a polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt
INVENTOR(S): **Blackler, Paul David James**; Browne, Christine Marie; Coakley, Timothy G.; Giles, Robert Gordon; Morrissey, Gillian
PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK; SmithKline Beecham (Cork) Limited
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064896	A1	20001102	WO 2000-GB1520	20000419
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1173435	A1	20020123	EP 2000-920892	20000419
EP 1173435	B1	20030730		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009932	A	20020409	BR 2000-9932	20000419
JP 2002543077	T2	20021217	JP 2000-614248	20000419
EP 1304330	A2	20030423	EP 2002-80321	20000419
EP 1304330	A3	20031119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 246191	E	20030815	AT 2000-920892	20000419
AU 765005	B2	20030904	AU 2000-41308	20000419
PT 1173435	T	20031231	PT 2000-920892	20000419
NZ 515168	A	20040227	NZ 2000-515168	20000419
NO 2001005147	A	20011217	NO 2001-5147	20011022
HR 2001000772	A1	20021031	HR 2001-772	20011022
ZA 2001008719	A	20020621	ZA 2001-8719	20011023
BG 106121	A	20020531	BG 2001-106121	20011120

PRIORITY APPLN. INFO.:
GB 1999-9473 A 19990423
GB 1999-12196 A 19990525
EP 2000-920892 A3 20000419
WO 2000-GB1520 W 20000419

AB A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt (the "Polymorph") characterized in that it provides: (i) an IR spectrum contg. peaks at 1763, 912, 856 and 709 cm^{-1}; and/or (ii) a Raman spectrum contg. peaks at 1762, 1284, 912 and 888 cm^{-1}; and/or (iii) a solid-state 13C NMR spectrum contg. peaks at 111.0, 113.6, 119.8, 129.1, 130.9, 131.8, 134.7, 138.7, 146.5, 152.7, 157.5, 169.5, 171.0, 178.7 ppm; and/or (iv) an x-ray powder diffraction (XRPD) pattern which gives calcd. lattice spacings at 5.87, 5.30, 4.69, 4.09, 3.88, 3.61, 3.53 and 3.46 Angstroms; a process for prepg. such a

compd., a pharmaceutical compn. contg. such a compd. and the use of such a compd. in medicine.

IT **155141-29-0**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antidiabetic action and properties of polymorphic form of [[(N-methyl-N-(pyridyl)amino)ethoxy]benzyl]thiazolidinedione maleate)

RN 155141-29-0 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:772627 HCAPLUS
DOCUMENT NUMBER: 133:340314
TITLE: Therapeutic action and properties of a polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt
INVENTOR(S): **Blackler, Paul David James**; Giles, Robert Gordon; Moore, Stephen; Sasse, Michael John
PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

10030877

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064893	A2	20001102	WO 2000-GB1522	20000419
WO 2000064893	A3	20010125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1175418	A2	20020130	EP 2000-922793	20000419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009935	A	20020416	BR 2000-9935	20000419
JP 2002543076	T2	20021217	JP 2000-614245	20000419
EP 1277753	A1	20030122	EP 2002-80319	20000419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NZ 515167	A	20040227	NZ 2000-515167	20000419
NO 2001005148	A	20011217	NO 2001-5148	20011022
HR 2001000774	A1	20021031	HR 2001-774	20011022
ZA 2001008718	A	20021203	ZA 2001-8718	20011023
BG 106122	A	20020531	BG 2001-106122	20011120

PRIORITY APPLN. INFO.:		
GB 1999-9471	A	19990423
GB 1999-12195	A	19990525
EP 2000-922793	A3	20000419
WO 2000-GB1522	W	20000419

AB A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the "Polymorph") characterized in that it provides: (i) an infra red spectrum contg. peaks at 1752, 1546, 1154, 621, and 602 cm^{-1}; and/or (ii) a Raman spectrum contg. peaks at 1751, 1243 and 602 cm^{-1}; and/or (iii) a solid-state NMR spectrum contg. peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0 and 175.0 ppm; and/or (iv) an x-ray powder diffraction (XRPD) pattern which gives calcd. lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for prepg. such a compd.,

a pharmaceutical compn. contg. such a compd. and the use of such a compd. in medicine.

IT **168553-12-6**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antidiabetic action of polymorphic form of [[(N-methyl-N-(pyridyl)amino)ethoxy]benzyl]thiazolidinedione maleate)

RN 168553-12-6 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L22 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:772626 HCAPLUS
DOCUMENT NUMBER: 133:340313
TITLE: Therapeutic action and properties of a polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt
INVENTOR(S): **Blackler, Paul David James**; Giles, Robert Gordon; Sasse, Michael John
PATENT ASSIGNEE(S): SmithKline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

Case 10703887

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064892	A2	20001102	WO 2000-GB1514	20000419
WO 2000064892	A3	20010125		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1173434	A2	20020123	EP 2000-920889	20000419
EP 1173434	B1	20030820		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009934	A	20020604	BR 2000-9934	20000419
JP 2002543075	T2	20021217	JP 2000-614244	20000419
EP 1284268	A1	20030219	EP 2002-80320	20000419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 247653	E	20030915	AT 2000-920889	20000419
AU 765498	B2	20030918	AU 2000-41306	20000419
PT 1173434	T	20031231	PT 2000-920889	20000419
NZ 515163	A	20040227	NZ 2000-515163	20000419
NO 2001005149	A	20011217	NO 2001-5149	20011022
HR 2001000773	A1	20021031	HR 2001-773	20011022
ZA 2001008722	A	20020911	ZA 2001-8722	20011023
BG 106119	A	20020531	BG 2001-106119	20011120

PRIORITY APPLN. INFO.:

GB 1999-9472	A	19990423
GB 1999-12197	A	19990525
EP 2000-920889	A3	20000419
WO 2000-GB1514	W	20000419

AB A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the "Polymorph") characterized in that it: (i) provides an IR spectrum contg. peaks at 1360, 1326, 1241, 714 and 669 cm^{-1}; and/or (ii) provides a Raman spectrum contg. peaks at 1581, 768, 670, 271 and 226 cm^{-1}; and/or (iii) provides a solid-state NMR spectrum contg. peaks at chem. shifts substantially; and/or (iv) provides an x-ray powder diffraction (XRPD) pattern contg. peaks; a process for

prepg. such a compd., a pharmaceutical compn. contg. such a compd. and the use of such a compd. in medicine.

IT **168553-12-6**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antidiabetic action of polymorphic form of [[(N-methyl-N-(pyridyl)amino)ethoxy]benzyl]thiazolidinedione maleate)

RN 168553-12-6 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L22 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:756704 HCAPLUS
DOCUMENT NUMBER: 133:325652
TITLE: 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride monohydrate pharmaceutical
INVENTOR(S): **Blackler, Paul David James**; Craig, Andrew Simon; Giles, Robert Gordon; Sasse, Michael John
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

US App 10/003,087

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063206	A2	20001026	WO 2000-GB1527	20000419
WO 2000063206	A3	20010222		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1173437	A2	20020123	EP 2000-920895	20000419
EP 1173437	B1	20040324		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009898	A	20020416	BR 2000-9898	20000419
JP 2002542243	T2	20021210	JP 2000-612296	20000419
NZ 515164	A	20040227	NZ 2000-515164	20000419
EP 1411054	A1	20040421	EP 2003-79072	20000419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NO 2001005105	A	20011219	NO 2001-5105	20011019
HR 2001000771	A1	20021231	HR 2001-771	20011019
ZA 2001008721	A	20020913	ZA 2001-8721	20011023
BG 106120	A	20020531	BG 2001-106120	20011120

PRIORITY APPLN. INFO.:

GB 1999-9075	A	19990420
EP 2000-920895	A3	20000419
WO 2000-GB1527	W	20000419

GI



I

AB 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride monohydrate (I.HCl.H2O) is characterized in that it: (i) provides an IR spectrum contg. peaks at 3358, 2764, 1245, 833 and 760 cm^{-1}; and/or (ii) provides an XRPD pattern contg. peaks at 15.0, 17.7, 23.0, 30.0 and 31.4 >2<j; a process for prepg. such a compd., a pharmaceutical compn. contg. such a compd. and the use of such a compd. in medicine.

IT **303082-83-9P**

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride monohydrate pharmaceutical)

RN 303082-83-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, monohydrochloride, monohydrate (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



HCl

H2O

L22 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:756703 HCAPLUS
DOCUMENT NUMBER: 133:313615
TITLE: Novel pharmaceutical thiazolidine derivative

INVENTOR(S): **Blackler, Paul David James**; Giles, Robert Gordon; Sasse, Michael John
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063205	A2	20001026	WO 2000-GB1521	20000419
WO 2000063205	A3	20010125		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000041309	A5	20001102	AU 2000-41309	20000419
EP 1173436	A2	20020123	EP 2000-920893	20000419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009897	A	20020416	BR 2000-9897	20000419
JP 2002542242	T2	20021210	JP 2000-612295	20000419
NZ 515166	A	20040227	NZ 2000-515166	20000419
EP 1411055	A1	20040421	EP 2003-79073	20000419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NO 2001005104	A	20011219	NO 2001-5104	20011019
HR 2001000770	A1	20021031	HR 2001-770	20011019
ZA 2001008720	A	20021128	ZA 2001-8720	20011023
BG 106112	A	20020531	BG 2001-106112	20011114
AU 2002027552	A5	20020516	AU 2002-27552	20020320
AU 765911	B2	20031002		

PRIORITY APPLN. INFO.:

GB 1999-9041	A	19990420
AU 2000-41309	A3	20000419
EP 2000-920893	A3	20000419
WO 2000-GB1521	W	20000419

AB 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride dihydrate is characterized by: (i) an IR spectrum contg. peaks at 3392, 2739, 1751, 1325 and 713 cm^{-1}, and/or (ii) an X-ray powder diffraction pattern contg. peaks at 9.1, 12.0, 15.7, 16.3 and 19.8°2θ. A process for prepg. this compd., a pharmaceutical compn. contg. such a compd. and its use for the treatment and/or prophylaxis of diabetes mellitus are described.

IT **302543-61-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn., properties, and compns. of antidiabetic thiazolidine deriv. as hydrochloride dihydrate)
RN 302543-61-9 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, monohydrochloride, dihydrate (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



HCl

2 H_2O

L22 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:404959 HCAPLUS
DOCUMENT NUMBER: 131:58818
TITLE: Preparation of a thiazolidinedione derivative as hydrate for prophylaxis or treatment of diabetes
INVENTOR(S): **Blackler, Paul David James**; Lee, David C.; Sasse, Michael John
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9931095	A1	19990624	WO 1998-EP8155	19981214

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2314107	AA	19990624	CA 1998-2314107	19981214
AU 9919679	A1	19990705	AU 1999-19679	19981214
EP 1040110	A1	20001004	EP 1998-964510	19981214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9813600	A	20001010	BR 1998-13600	19981214
JP 2002508373	T2	20020319	JP 2000-539019	19981214
ZA 9811506	A	20001106	ZA 1998-11506	19981215
EG 22337	A	20021231	EG 1998-1556	19981215
TW 509690	B	20021111	TW 1998-87121121	19981216
NO 2000003069	A	20000615	NO 2000-3069	20000615
HR 2000000408	A1	20000831	HR 2000-408	20000616
BG 104603	A	20010330	BG 2000-104603	20000713
US 2002137940	A1	20020926	US 2002-82879	20020226
US 2003120078	A1	20030626	US 2002-321055	20021217

PRIORITY APPLN. INFO.:

GB 1997-26566	A	19971216
WO 1998-EP8155	W	19981214
US 2000-581826	B1	20000616
US 2002-82879	B1	20020226

AB Prepn. of a hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate (I) for prophylaxis and/or treatment of diabetes mellitus and conditions assocd. with it is described. The compd. comprises water in the range of 0.4-2.5% wt./wt. and provides a specific IR spectrum, an X-ray powder diffraction pattern, a Raman spectrum, and/or a solid-state NMR spectrum. I with the water content of 0.54% wt./wt. was prepd. from 6 g of the I free base and 2.1 g maleic acid salt by heating in MeOH to 55° to obtain a soln.; the soln. was filtered, reheated at 55°, and then cooled to 0-5° and stirred. The product was filtered and dried at 52° in vacuo to give I in 84% yield (6.7 g).

IT **227606-02-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of thiazolidinedione deriv. as hydrate for prophylaxis or treatment of diabetes)

RN 227606-02-2 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1), hydrate (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:404958 HCAPLUS
DOCUMENT NUMBER: 131:63474
TITLE: Hydrate of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
INVENTOR(S): **Blackler, Paul David James**; Lee, David C.; Sasse, Michael John
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9931094	A1	19990624	WO 1998-EP8154	19981214
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2314965	AA	19990624	CA 1998-2314965	19981214
AU 9922723	A1	19990705	AU 1999-22723	19981214
BR 9813604	A	20001010	BR 1998-13604	19981214
EP 1045847	A1	20001025	EP 1998-966321	19981214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002508372	T2	20020319	JP 2000-539018	19981214
NZ 504704	A	20030328	NZ 1998-504704	19981214
IL 136381	A1	20030917	IL 1998-136381	19981214
ZA 9811505	A	20001106	ZA 1998-11505	19981215
EG 21417	A	20011031	EG 1998-1554	19981215
TW 467913	B	20011211	TW 1998-87121122	19981216
NO 2000003068	A	20000615	NO 2000-3068	20000615
HR 2000000405	A1	20001231	HR 2000-405	20000616
BG 104595	A	20010228	BG 2000-104595	20000711
US 2002099081	A1	20020725	US 2002-72096	20020207
US 6664278	B2	20031216		

PRIORITY APPLN. INFO.:		
GB 1997-26568	A	19971216
WO 1998-EP8154	W	19981214
US 2000-581719	A1	20000616

AB A hydrate of the title compd. is prepd. which is useful in treatment and/or prophylaxis of diabetes mellitus and its complications and assocd. conditions such as insulin resistance, impaired glucose tolerance, hyperinsulinemia, obesity, and gestational diabetes, and is particularly suitable for bulk prepn. and handling. The hydrate is characterized by a water content of 0.2-1.1 wt.% and by its IR spectrum and x-ray powder diffraction pattern. The hydrate is prepd. by crystn. from an aq. alkanol, preferably contg. 2.0-2.5 vol.% water.

IT **227606-02-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(hydrate of antidiabetic thiazolidinedione deriv.)

RN 227606-02-2 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1), hydrate (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4

CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:772629 HCAPLUS
DOCUMENT NUMBER: 133:340315
TITLE: Therapeutic action and properties of a polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt
INVENTOR(S): **Blackler, Paul David James**; Browne, Christine Marie; Coakley, Timothy G.; Giles, Robert Gordon; Morrissey, Gillian
PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK; SmithKline Beecham (Cork) Limited
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064896	A1	20001102	WO 2000-GB1520	20000419
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1173435	A1	20020123	EP 2000-920892	20000419
EP 1173435	B1	20030730		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009932	A	20020409	BR 2000-9932	20000419
JP 2002543077	T2	20021217	JP 2000-614248	20000419
EP 1304330	A2	20030423	EP 2002-80321	20000419
EP 1304330	A3	20031119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 246191	E	20030815	AT 2000-920892	20000419
AU 765005	B2	20030904	AU 2000-41308	20000419
PT 1173435	T	20031231	PT 2000-920892	20000419
NZ 515168	A	20040227	NZ 2000-515168	20000419
NO 2001005147	A	20011217	NO 2001-5147	20011022
HR 2001000772	A1	20021031	HR 2001-772	20011022
ZA 2001008719	A	20020621	ZA 2001-8719	20011023
BG 106121	A	20020531	BG 2001-106121	20011120

PRIORITY APPLN. INFO.:		
GB 1999-9473	A	19990423
GB 1999-12196	A	19990525
EP 2000-920892	A3	20000419
WO 2000-GB1520	W	20000419

AB A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt (the "Polymorph") characterized in that it provides: (i) an IR spectrum contg. peaks at 1763, 912, 856 and 709 cm^{-1}; and/or (ii) a Raman spectrum contg. peaks at 1762, 1284, 912 and 888 cm^{-1}; and/or (iii) a solid-state 13C NMR spectrum contg. peaks at 111.0, 113.6, 119.8, 129.1, 130.9, 131.8, 134.7, 138.7, 146.5, 152.7, 157.5, 169.5, 171.0, 178.7 ppm; and/or (iv) an x-ray powder diffraction (XRPD) pattern which gives calcd. lattice spacings at 5.87, 5.30, 4.69, 4.09, 3.88, 3.61, 3.53 and 3.46 Angstroms; a process for prepg. such a compd., a pharmaceutical compn. contg. such a compd. and the use of such a compd. in medicine.

IT **155141-29-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antidiabetic action and properties of polymorphic form of [[(N-methyl-N-(pyridyl)amino)ethoxy]benzyl]thiazolidinedione maleate)
RN 155141-29-0 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:772627 HCAPLUS
DOCUMENT NUMBER: 133:340314
TITLE: Therapeutic action and properties of a polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt
INVENTOR(S): **Blackler, Paul David James**; Giles, Robert Gordon;

Moore, Stephen; Sasse, Michael John
PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064893	A2	20001102	WO 2000-GB1522	20000419
WO 2000064893	A3	20010125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1175418	A2	20020130	EP 2000-922793	20000419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009935	A	20020416	BR 2000-9935	20000419
JP 2002543076	T2	20021217	JP 2000-614245	20000419
EP 1277753	A1	20030122	EP 2002-80319	20000419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NZ 515167	A	20040227	NZ 2000-515167	20000419
NO 2001005148	A	20011217	NO 2001-5148	20011022
HR 2001000774	A1	20021031	HR 2001-774	20011022
ZA 2001008718	A	20021203	ZA 2001-8718	20011023
BG 106122	A	20020531	BG 2001-106122	20011120

PRIORITY APPLN. INFO.:

GB 1999-9471	A	19990423
GB 1999-12195	A	19990525
EP 2000-922793	A3	20000419
WO 2000-GB1522	W	20000419

AB A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the "Polymorph") characterized in that it provides: (i) an infra red spectrum contg. peaks at 1752, 1546, 1154, 621, and 602 cm^{-1}; and/or (ii) a Raman spectrum contg. peaks at 1751, 1243 and 602 cm^{-1}; and/or (iii) a solid-state NMR spectrum contg. peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0 and 175.0 ppm; and/or (iv) an x-ray powder diffraction (XRPD) pattern which gives calcd. lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for prepg. such a compd., a pharmaceutical compn. contg. such a compd. and the use of such a compd. in medicine.

IT **168553-12-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antidiabetic action of polymorphic form of [[(N-methyl-N-(pyridyl)amino)ethoxy]benzyl]thiazolidinedione maleate)

RN 168553-12-6 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L22 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:772626 HCAPLUS
DOCUMENT NUMBER: 133:340313
TITLE: Therapeutic action and properties of a polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt
INVENTOR(S): **Blackler, Paul David James**; Giles, Robert Gordon; Sasse, Michael John
PATENT ASSIGNEE(S): SmithKline Beecham P.L.C., UK

SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064892	A2	20001102	WO 2000-GB1514	20000419
WO 2000064892	A3	20010125		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1173434	A2	20020123	EP 2000-920889	20000419
EP 1173434	B1	20030820		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009934	A	20020604	BR 2000-9934	20000419
JP 2002543075	T2	20021217	JP 2000-614244	20000419
EP 1284268	A1	20030219	EP 2002-80320	20000419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 247653	E	20030915	AT 2000-920889	20000419
AU 765498	B2	20030918	AU 2000-41306	20000419
PT 1173434	T	20031231	PT 2000-920889	20000419
NZ 515163	A	20040227	NZ 2000-515163	20000419
NO 2001005149	A	20011217	NO 2001-5149	20011022
HR 2001000773	A1	20021031	HR 2001-773	20011022
ZA 2001008722	A	20020911	ZA 2001-8722	20011023
BG 106119	A	20020531	BG 2001-106119	20011120

PRIORITY APPLN. INFO.:

GB 1999-9472	A	19990423
GB 1999-12197	A	19990525
EP 2000-920889	A3	20000419
WO 2000-GB1514	W	20000419

AB A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the "Polymorph") characterized in that it: (i) provides an IR spectrum contg. peaks at 1360, 1326, 1241, 714 and 669 cm^{-1}; and/or (ii) provides a Raman spectrum contg. peaks at 1581, 768, 670, 271 and 226 cm^{-1}; and/or (iii) provides a solid-state NMR spectrum contg. peaks at chem. shifts substantially; and/or (iv) provides an x-ray powder diffraction (XRPD) pattern contg. peaks; a process for prepg. such a compd., a pharmaceutical compn. contg. such a compd. and the use of such a compd. in medicine.

IT **168553-12-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antidiabetic action of polymorphic form of [[(N-methyl-N-(pyridyl)amino)ethoxy]benzyl]thiazolidinedione maleate)

RN 168553-12-6 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L22 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:756704 HCAPLUS
DOCUMENT NUMBER: 133:325652
TITLE: 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride monohydrate pharmaceutical
INVENTOR(S): **Blackler, Paul David James**; Craig, Andrew Simon; Giles, Robert Gordon; Sasse, Michael John
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 15 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063206	A2	20001026	WO 2000-GB1527	20000419
WO 2000063206	A3	20010222		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1173437	A2	20020123	EP 2000-920895	20000419
EP 1173437	B1	20040324		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009898	A	20020416	BR 2000-9898	20000419
JP 2002542243	T2	20021210	JP 2000-612296	20000419
NZ 515164	A	20040227	NZ 2000-515164	20000419
EP 1411054	A1	20040421	EP 2003-79072	20000419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NO 2001005105	A	20011219	NO 2001-5105	20011019
HR 2001000771	A1	20021231	HR 2001-771	20011019
ZA 2001008721	A	20020913	ZA 2001-8721	20011023
BG 106120	A	20020531	BG 2001-106120	20011120

PRIORITY APPLN. INFO.:

GB 1999-9075	A	19990420
EP 2000-920895	A3	20000419
WO 2000-GB1527	W	20000419

GI



I

AB 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride monohydrate (I.HCl.H2O) is characterized in that it: (i) provides an IR spectrum contg. peaks at 3358, 2764, 1245, 833 and 760 cm^{-1}; and/or (ii) provides an XRPD pattern contg. peaks at 15.0, 17.7, 23.0, 30.0 and 31.4 >2<j; a process for prepg. such a compd., a pharmaceutical compn. contg. such a compd. and the use of such a compd. in medicine.

IT **303082-83-9P**
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride monohydrate pharmaceutical)

RN 303082-83-9 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, monohydrochloride, monohydrate (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



HCl

H_2O

L22 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:756703 HCAPLUS
DOCUMENT NUMBER: 133:313615
TITLE: Novel pharmaceutical thiazolidine derivative
INVENTOR(S): **Blackler, Paul David James**; Giles, Robert Gordon; Sasse, Michael John
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2000063205	A2	20001026	WO 2000-GB1521	20000419	
WO 2000063205	A3	20010125			
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 2000041309	A5	20001102	AU 2000-41309	20000419	
EP 1173436	A2	20020123	EP 2000-920893	20000419	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
BR 2000009897	A	20020416	BR 2000-9897	20000419	
JP 2002542242	T2	20021210	JP 2000-612295	20000419	
NZ 515166	A	20040227	NZ 2000-515166	20000419	
EP 1411055	A1	20040421	EP 2003-79073	20000419	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
NO 2001005104	A	20011219	NO 2001-5104	20011019	
HR 2001000770	A1	20021031	HR 2001-770	20011019	
ZA 2001008720	A	20021128	ZA 2001-8720	20011023	
BG 106112	A	20020531	BG 2001-106112	20011114	
AU 2002027552	A5	20020516	AU 2002-27552	20020320	
AU 765911	B2	20031002			

PRIORITY APPLN. INFO.:

GB 1999-9041	A	19990420
AU 2000-41309	A3	20000419
EP 2000-920893	A3	20000419
WO 2000-GB1521	W	20000419

AB 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride dihydrate is characterized by: (i) an IR spectrum contg. peaks at 3392, 2739, 1751, 1325 and 713 cm^{-1}, and/or (ii) an X-ray powder diffraction pattern contg. peaks at 9.1, 12.0, 15.7, 16.3 and 19.8°2θ. A process for prepg. this compd., a pharmaceutical compn. contg. such a compd. and its use for the treatment and/or prophylaxis of diabetes mellitus are described.

IT **302543-61-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn., properties, and compns. of antidiabetic thiazolidine deriv. as hydrochloride dihydrate)

RN 302543-61-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, monohydrochloride, dihydrate (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



HCl

2 H_2O

L22 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:404959 HCAPLUS
DOCUMENT NUMBER: 131:58818
TITLE: Preparation of a thiazolidinedione derivative as hydrate for prophylaxis or treatment of diabetes
INVENTOR(S): **Blackler, Paul David James**; Lee, David C.; Sasse, Michael John
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9931095	A1	19990624	WO 1998-EP8155	19981214

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,

MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2314107	AA	19990624	CA 1998-2314107	19981214
AU 9919679	A1	19990705	AU 1999-19679	19981214
EP 1040110	A1	20001004	EP 1998-964510	19981214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9813600	A	20001010	BR 1998-13600	19981214
JP 2002508373	T2	20020319	JP 2000-539019	19981214
ZA 9811506	A	20001106	ZA 1998-11506	19981215
EG 22337	A	20021231	EG 1998-1556	19981215
TW 509690	B	20021111	TW 1998-87121121	19981216
NO 2000003069	A	20000615	NO 2000-3069	20000615
HR 2000000408	A1	20000831	HR 2000-408	20000616
BG 104603	A	20010330	BG 2000-104603	20000713
US 2002137940	A1	20020926	US 2002-82879	20020226
US 2003120078	A1	20030626	US 2002-321055	20021217

PRIORITY APPLN. INFO.:

GB 1997-26566	A	19971216
WO 1998-EP8155	W	19981214
US 2000-581826	B1	20000616
US 2002-82879	B1	20020226

AB Prepn. of a hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate (I) for prophylaxis and/or treatment of diabetes mellitus and conditions assocd. with it is described. The compd. comprises water in the range of 0.4-2.5% wt./wt. and provides a specific IR spectrum, an X-ray powder diffraction pattern, a Raman spectrum, and/or a solid-state NMR spectrum. I with the water content of 0.54% wt./wt. was prepd. from 6 g of the I free base and 2.1 g maleic acid salt by heating in MeOH to 55° to obtain a soln.; the soln. was filtered, reheated at 55°, and then cooled to 0-5° and stirred. The product was filtered and dried at 52° in vacuo to give I in 84% yield (6.7 g).

IT **227606-02-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of thiazolidinedione deriv. as hydrate for prophylaxis or treatment of diabetes)

RN 227606-02-2 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1), hydrate (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:404958 HCAPLUS
DOCUMENT NUMBER: 131:63474
TITLE: Hydrate of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
INVENTOR(S): **Blackler, Paul David James**; Lee, David C.; Sasse, Michael John
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9931094	A1	19990624	WO 1998-EP8154	19981214
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2314965	AA	19990624	CA 1998-2314965	19981214
AU 9922723	A1	19990705	AU 1999-22723	19981214
BR 9813604	A	20001010	BR 1998-13604	19981214
EP 1045847	A1	20001025	EP 1998-966321	19981214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002508372	T2	20020319	JP 2000-539018	19981214
NZ 504704	A	20030328	NZ 1998-504704	19981214
IL 136381	A1	20030917	IL 1998-136381	19981214
ZA 9811505	A	20001106	ZA 1998-11505	19981215
EG 21417	A	20011031	EG 1998-1554	19981215
TW 467913	B	20011211	TW 1998-87121122	19981216
NO 2000003068	A	20000615	NO 2000-3068	20000615
HR 2000000405	A1	20001231	HR 2000-405	20000616
BG 104595	A	20010228	BG 2000-104595	20000711
US 2002099081	A1	20020725	US 2002-72096	20020207
US 6664278	B2	20031216		

PRIORITY APPLN. INFO.:			
GB 1997-26568	A	19971216	
WO 1998-EP8154	W	19981214	
US 2000-581719	A1	20000616	

AB A hydrate of the title compd. is prepd. which is useful in treatment and/or prophylaxis of diabetes mellitus and its complications and assocd. conditions such as insulin resistance, impaired glucose tolerance, hyperinsulinemia, obesity, and gestational diabetes, and is particularly suitable for bulk prepn. and handling. The hydrate is characterized by a water content of 0.2-1.1 wt.% and by its IR spectrum and x-ray powder diffraction pattern. The hydrate is prepd. by crystn. from an aq. alkanol, preferably contg. 2.0-2.5 vol.% water.

IT **227606-02-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(hydrate of antidiabetic thiazolidinedione deriv.)

RN 227606-02-2 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1), hydrate (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4

CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 12:12:32 ON 26 APR 2004)

FILE 'REGISTRY' ENTERED AT 12:12:37 ON 26 APR 2004
L1 STRUCTURE UPLOADED
L2 5 S L1
L3 115 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 12:16:42 ON 26 APR 2004
L4 892 S L3

FILE 'REGISTRY' ENTERED AT 12:17:12 ON 26 APR 2004
L5 STRUCTURE UPLOADED
L6 0 S L5

```
L7              0 S L5 FULL
L8                STRUCTURE UPLOADED
L9              4 S L8
L10           103 S L8 FULL

     FILE 'HCAPLUS' ENTERED AT 12:21:24 ON 26 APR 2004
L11           892 S L10
L12               STRUCTURE UPLOADED
                  S L12

     FILE 'REGISTRY' ENTERED AT 12:23:45 ON 26 APR 2004
L13             4 S L12

     FILE 'HCAPLUS' ENTERED AT 12:23:46 ON 26 APR 2004
L14             4 S L13
L15               STRUCTURE UPLOADED
                  S L15

     FILE 'REGISTRY' ENTERED AT 12:24:18 ON 26 APR 2004
L16             4 S L15

     FILE 'HCAPLUS' ENTERED AT 12:24:19 ON 26 APR 2004
L17             4 S L16

     FILE 'REGISTRY' ENTERED AT 12:25:51 ON 26 APR 2004
L18               STRUCTURE UPLOADED
L19             4 S L18
L20           101 S L18 FULL

     FILE 'HCAPLUS' ENTERED AT 12:26:18 ON 26 APR 2004
L21           891 S L20
L22             7 S L4 AND BLACKLER, P?/AU

=> s l21 not l22
L23           884 L21 NOT L22

=> s l23 and giles, r?/au
            441 GILES, R?/AU
L24           3 L23 AND GILES, R?/AU

=> s l24 not l22
L25           3 L24 NOT L22

=> d l25, ibib abs fhitstr, 1-3

L25  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2004 ACS on STN
```


```
ACCESSION NUMBER:         2000:458470  HCAPLUS
DOCUMENT NUMBER:          133:222646
TITLE:                    Regiospecific reduction of 5-benzylidene-2,4-
                          thiazolidinediones and 4-oxo-2-thiazolidinethiones
                          using lithium borohydride in pyridine and
                          tetrahydrofuran
AUTHOR(S):                Giles, Robert G.; Lewis, Norman J.; Quick, John K.;
                          Sasse, Michael J.; Urquhart, Michael W. J.; Youssef,
                          Latifa
CORPORATE SOURCE:         SmithKline Beecham Pharmaceuticals, Old Powder Mills,
                          Kent, TN11 9AN, UK
SOURCE:                   Tetrahedron (2000), 56(26), 4531-4537
```

CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:222646
GI



I

AB The novel regiospecific and general redn. of 5-benzylidene-2,4-thiazolidinediones and 5-benzylidene-4-oxo-2-thiazolidinethiones to the corresponding 5-benzyl derivs. was accomplished using LiBH4 in pyridine and THF. NaBH4 and LiCl can also be used under these conditions, which represents a cheaper alternative to LiBH4. Thus, redn. of benzylideneoxothiazolidinethione I (R1 = R2 = R3 = H, R4 = Me, X = S) with LiBH4 in THF/pyridine for 5 h afforded the benzyl deriv. in 96% yield.

IT **122320-73-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:311203 HCAPLUS
DOCUMENT NUMBER: 130:313481
TITLE: Process for the preparation of thiazolidinedione derivatives
INVENTOR(S): **Giles, Robert Gordon**; Lewis, Norman John; Quick, John Kirby
PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK
SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9923095	A1	19990514	WO 1998-EP6997	19981027
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2309461	AA	19990514	CA 1998-2309461	19981027
AU 9915595	A1	19990524	AU 1999-15595	19981027
EP 1028960	A1	20000823	EP 1998-959834	19981027
EP 1028960	B1	20030423		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9814622	A	20001003	BR 1998-14622	19981027
JP 2001521937	T2	20011113	JP 2000-518965	19981027
EP 1219620	A1	20020703	EP 2002-75969	19981027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL				
AT 238302	E	20030515	AT 1998-959834	19981027
PT 1028960	T	20030930	PT 1998-959834	19981027
ES 2197519	T3	20040101	ES 1998-959834	19981027
ZA 9810033	A	20000503	ZA 1998-10033	19981103
NO 2000002174	A	20000530	NO 2000-2174	20000427
HR 2000000263	A1	20001231	HR 2000-263	20000504
BG 104505	A	20010131	BG 2000-104505	20000605
HK 1032046	A1	20040130	HK 2001-100772	20010202
US 2002120150	A1	20020829	US 2002-82995	20020226
US 2003092742	A1	20030515	US 2002-288072	20021104

PRIORITY APPLN. INFO.:

GB 1997-23295	A	19971104
EP 1998-959834	A3	19981027
WO 1998-EP6997	W	19981027
US 2000-530888	B1	20000710
US 2002-82995	B1	20020226

OTHER SOURCE(S): MARPAT 130:313481
GI



AB Title compds. such as I are prepd. by hydrogenation of their benzylidenethiazolidinone analogs. Thus, 123 kg (Z)-5-[4-[2-(methyl-2-pyridylamino)ethoxy]benzylidene]-2,4-thiazolidinedione in 1232 L glacial HOAc is hydrogenated at 70-80 psi H2 over 10% Pd/charcoal at about 90° to give I in 70-80% yield.

IT **122320-73-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1998:604911 HCAPLUS
DOCUMENT NUMBER: 129:202936
TITLE: Preparation of 5-benzylthiazolidine-2,4-diones.
INVENTOR(S): **Giles, Robert Gordon**; Lewis, Norman John; Moore, Stephen; Pool, Colin Ripley; Quick, John Kirby;

	Urquhart, Michael
PATENT ASSIGNEE(S):	Smithkline Beecham PLC, UK
SOURCE:	PCT Int. Appl., 26 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9837073	A1	19980827	WO 1998-EP818	19980213
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9866223	A1	19980909	AU 1998-66223	19980213
EP 970063	A1	20000112	EP 1998-908093	19980213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 9807395	A	20000314	BR 1998-7395	19980213
NZ 337179	A	20010727	NZ 1998-337179	19980213
JP 2001514619	T2	20010911	JP 1998-536229	19980213
ZA 9801280	A	19990817	ZA 1998-1280	19980217
IN 188379	A	20020914	IN 1998-DE417	19980218
NO 9903949	A	19990907	NO 1999-3949	19990817
MX 9907656	A	20000228	MX 1999-7656	19990818
US 2002042519	A1	20020411	US 2001-5686	20011108
US 6632947	B2	20031014		
NO 2002003937	A	19990907	NO 2002-3937	20020819

PRIORITY APPLN. INFO.:	GB 1997-3310	A	19970218
	GB 1997-3334	A	19970218
	GB 1997-3338	A	19970218
	WO 1998-EP818	W	19980213
	US 1999-367757	A1	19990818

OTHER SOURCE(S): CASREACT 129:202936; MARPAT 129:202936

GI



AB Title compds. (I; J, T1 = O, S; T = (substituted) aryl) were prepd. by reducing alkenes (II; variables as above) with a complex hydride reducing agent or a source of a complex hydride reducing agent. Thus, 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzylidene]-2,4-thiazolidinedione was refluxed with Li tri-sec-butylborohydride in THF to give 79% 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]-2,4-thiazolidinedione.

IT **122320-73-4P**

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 5-benzylthiazolidine-2,4-diones)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 12:12:32 ON 26 APR 2004)

FILE 'REGISTRY' ENTERED AT 12:12:37 ON 26 APR 2004

L1 STRUCTURE UPLOADED

L2 5 S L1

L3 115 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 12:16:42 ON 26 APR 2004

L4 892 S L3

FILE 'REGISTRY' ENTERED AT 12:17:12 ON 26 APR 2004

L5 STRUCTURE UPLOADED

L6 0 S L5

L7 0 S L5 FULL

L8 STRUCTURE UPLOADED

L9 4 S L8

L10 103 S L8 FULL

```
     FILE 'HCAPLUS' ENTERED AT 12:21:24 ON 26 APR 2004
L11          892 S L10
L12              STRUCTURE UPLOADED
                 S L12

     FILE 'REGISTRY' ENTERED AT 12:23:45 ON 26 APR 2004
L13            4 S L12

     FILE 'HCAPLUS' ENTERED AT 12:23:46 ON 26 APR 2004
L14            4 S L13
L15              STRUCTURE UPLOADED
                 S L15

     FILE 'REGISTRY' ENTERED AT 12:24:18 ON 26 APR 2004
L16            4 S L15

     FILE 'HCAPLUS' ENTERED AT 12:24:19 ON 26 APR 2004
L17            4 S L16

     FILE 'REGISTRY' ENTERED AT 12:25:51 ON 26 APR 2004
L18              STRUCTURE UPLOADED
L19            4 S L18
L20          101 S L18 FULL

     FILE 'HCAPLUS' ENTERED AT 12:26:18 ON 26 APR 2004
L21          891 S L20
L22            7 S L4 AND BLACKLER, P?/AU
L23          884 S L21 NOT L22
L24            3 S L23 AND GILES, R?/AU
L25            3 S L24 NOT L22

=> s l4 and sase, m?/au
            53 SASE, M?/AU
L26          0 L4 AND SASE, M?/AU

=>
```